REPLIGEN CORPORATION

RGEN · NASDAQ

Biological Product (except Diagnostic) Manufacturing · US

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Its primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Its corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of its manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. it has sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

Market Data

Price $121.79 -6.10 (-4.77%)

Market Cap$6.86B

P/E Ratio140.32

EPS$—

52W High$175.77

52W Low$102.97

Beta1.19

Data from Finnhub · Updated Mar 11, 2026